Featured Articles

  • Visible particulates in cell therapy: Industry looks toward a more realistic standard

    Wednesday, April 15, 2026
    The cell therapy sector remains constrained by particulate guidance based on traditional parenteral products, says a BioPhorum publication. read more

  • Navigating material demands of next-gen CGTs

    Wednesday, April 01, 2026
    Cultivating resilient, stage-appropriate supply strategies is an essential yet often overlooked part of delivering safe, effective therapies to patients. read more

  • Electroporation-based delivery for gene editing

    Wednesday, March 25, 2026
    New findings establish the feasibility of combining nonviral ex vivo gene editing, hepatocyte transplantation, and in vivo selection, and support the clinical translation of cell-based gene-editing therapies for inherited metabolic liver ... read more

  • Reaping the spoils of CGT’s golden age

    Tuesday, March 10, 2026
    We are living in the golden age of cell and gene therapy — but the spoils will go to those who chart a deliberate course, choose the right partners, and translate breakthrough science into sustainable commercial reality. read more

  • Preclinical roadmap to first-in-human

    Thursday, March 05, 2026
    A well-designed development roadmap can be a powerful strategic asset — shaping investor confidence and guiding capital deployment. Yet questions persist around the optimal timing for roadmap buildout and how it should evolve alongside ... read more

  • From pirates to powerhouse

    Tuesday, February 24, 2026
    The evolution from imitation to innovation has created an ecosystem designed to reward novel science and transformative treatment approaches — and Swiss companies are now claiming their stake. read more

  • Swimming upstream

    Wednesday, February 18, 2026
    Rare and ultra-rare disease patients have long been forced to struggle upstream. read more

  • 2026 cell and gene therapy predictions

    Monday, February 09, 2026
    As advanced therapies transition from promising science to industrial maturity, investors will increasingly favor late-stage programs with strong data, proven scalability and credible paths to adoption. read more

  • From centralized to decentralized

    Wednesday, February 04, 2026
    A decentralized model for cell-based products offers various benefits including fresh tissues and drug products, reduced costs, and shorter treatment times. read more

  • Narrowing the CGT access gap

    Tuesday, January 27, 2026
    There is significant opportunity to expand the applications of cell therapy further into rare diseases as well as to tackle widespread conditions. read more

  • What sponsors should know about FDA’s platform technology designation

    Tuesday, January 20, 2026
    Sponsors with a licensed gene therapy can use the same vector platform to reference manufacturing, analytical and safety data for other candidates. read more

  • Little fish, big waves

    Tuesday, January 13, 2026
    A powerful shift is underway within the rare disease space. It started as a handful of inspiring stories of parents stopping at nothing to save the lives of their children. But while this patient advocacy-driven movement is compelling — it ... read more
Page